home / stock / acet / acet quote
Last: | $1.40 |
---|---|
Change Percent: | -6.02% |
Open: | $1.41 |
Close: | $1.40 |
High: | $1.53 |
Low: | $1.38 |
Volume: | 2,664,779 |
Last Trade Date Time: | 05/15/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.4 | $1.41 | $1.4 | $1.53 | $1.38 | 2,664,779 | 05-15-2024 |
$1.33 | $1.49 | $1.33 | $1.51 | $1.33 | 1,016,861 | 05-14-2024 |
$1.44 | $1.5 | $1.44 | $1.555 | $1.43 | 877,563 | 05-13-2024 |
$1.47 | $1.73 | $1.47 | $1.73 | $1.46 | 939,720 | 05-10-2024 |
$1.63 | $1.66 | $1.63 | $1.7 | $1.62 | 440,942 | 05-09-2024 |
$1.65 | $1.7 | $1.65 | $1.81 | $1.63 | 998,685 | 05-08-2024 |
$1.73 | $1.67 | $1.73 | $1.865 | $1.66 | 1,612,871 | 05-07-2024 |
$1.69 | $1.49 | $1.69 | $1.71 | $1.49 | 3,091,362 | 05-06-2024 |
$1.45 | $1.45 | $1.45 | $1.56 | $1.4 | 4,866,272 | 05-03-2024 |
$1.41 | $1.51 | $1.41 | $1.55 | $1.39 | 4,877,852 | 05-02-2024 |
$1.52 | $1.55 | $1.52 | $1.63 | $1.51 | 3,886,748 | 05-01-2024 |
$1.49 | $1.59 | $1.49 | $1.68 | $1.45 | 2,121,565 | 04-30-2024 |
$1.59 | $1.7 | $1.59 | $1.765 | $1.59 | 1,605,582 | 04-29-2024 |
$1.68 | $1.81 | $1.68 | $1.825 | $1.66 | 1,251,696 | 04-26-2024 |
$1.81 | $1.89 | $1.81 | $1.95 | $1.8 | 851,580 | 04-25-2024 |
$1.875 | $2.07 | $1.875 | $2.08 | $1.865 | 1,352,764 | 04-24-2024 |
$2.1 | $2.14 | $2.1 | $2.25 | $2.07 | 1,147,946 | 04-23-2024 |
$2 | $2 | $2 | $2.045 | $1.955 | 325,351 | 04-22-2024 |
$1.95 | $2.01 | $1.95 | $2.035 | $1.9 | 727,751 | 04-19-2024 |
$2.025 | $2.29 | $2.025 | $2.29 | $2.005 | 930,124 | 04-18-2024 |
News, Short Squeeze, Breakout and More Instantly...
On track to initiate Phase 1 clinical trial evaluating ADI-001 in lupus nephritis in 2Q 2024 Presented promising preclinical data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting; on track to file investigational new drug (IND) in renal cell carcinoma in ...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming European Hematology Association (EHA) Hybrid Congr...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2024 Ci...